11 results
8-K
EX-99.1
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
16 Oct 23
Regulation FD Disclosure
6:16am
: “The overall data package created with the MIRA trial establishes MoonLake’s position as a leading innovator in the Immunology and Inflammation (I&I) and IL-17 … creates, in my opinion, a unique Phase 2 data package, for a disease that has proven to be extremely challenging to treat.”
Joslyn Kirby, MD, MEd, MS
8-K
EX-1.1
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
29 Jun 23
Entry into a Material Definitive Agreement
4:13pm
by the Company and the Representatives.
“General Disclosure Package” means any Issuer Free Writing Prospectuses issued at or prior to the Applicable Time … of (A) the General Disclosure Package, nor (B) any individual Written Testing-the-Waters Communication, when considered together with the General
DEFA14A
w6cgclq5ux18fwwukuc
19 Jan 22
Additional proxy soliciting materials
12:00am
DEFA14A
EX-99.2
myh4nkyg
4 Oct 21
Additional proxy soliciting materials
7:13am
8-K
EX-99.2
uryrx17kvo74
4 Oct 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-1.1
mn1up
22 Oct 20
Helix Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
5:06pm
S-1/A
EX-1.1
b36 2lp2g1jbx
14 Oct 20
IPO registration (amended)
10:23am
- Prev
- 1
- Next